Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, allowing the company to move to larger trials for pulmonary hypertension (PH) associated with interstitial lung disease. eNOfit is designed to provide patients with mobile treatment…
News
Aria CV’s second-generation medical device for treating people with pulmonary arterial hypertension (PAH) — a balloon system known as the Gen 2 — has been successfully implanted in the first patient taking part in a U.S. study, according to a company press release. The…
A research project to help shed light about why people with the human immunodeficiency virus (HIV) are at higher risk for developing pulmonary hypertension (PH) was awarded a $2.67 million grant. The four-year grant from the National Heart, Lung and Blood Institute, part of the…
The Pulmonary Hypertension Association (PHA) will host a free workshop and fundraiser April 6-7 in Houston to raise awareness for pulmonary hypertension (PH) and support the greater PH community. The highlight of the weekend’s activities, which are aimed at educating, empowering, and supporting patients and caregivers, will be…
Tenax Therapeutics has secured global rights to oral and subcutaneous (under the skin) formulations of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Under a licensing agreement established with Orion Corp. in 2013, Tenax acquired developmental and commercial rights of…
People with pulmonary hypertension (PH) and high blood acetylcholine (ACh) levels show more severe symptoms and a poorer prognosis than those with lower ACh levels, a single-center study in China suggests. ACh is a neurotransmitter, a chemical messenger that allows nerve cells to communicate…
The hormone vasopressin may help improve oxygen levels and blood flow in newborns with acute pulmonary hypertension who fail to respond to treatment with inhaled nitric oxide, a study suggests. About two-thirds of newborns treated with vasopressin in the study, however, developed hyponatremia (a low level of sodium in…
The first healthy volunteer has been dosed in a Phase 1 trial testing ZMA001, Zymedi’s first-in-class investigational therapy for pulmonary arterial hypertension (PAH). The trial (NCT05967299), still recruiting participants at a clinical center in Bethesda, Maryland, will evaluate the safety, tolerability, and pharmacological properties of ZMA001.
Access to pulmonary rehabilitation programs for people with pulmonary hypertension (PH) and other chronic respiratory conditions is considerably more difficult for those living in rural U.S. regions than in urban areas, scientists report. Travel longer than 60 minutes affects more than 14 million U.S. residents of rural or underpopulated…
A Phase 3 trial of an oral formulation of levosimendan, dubbed TNX-103, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has enrolled the first participant. LEVEL (NCT05983250) is recruiting up to 152 adults with PH-HFpEF, ages 18-85,…
An inflammatory protein called CIRP may serve as a marker of pulmonary hypertension (PH) in people with chronic obstructive pulmonary disease (COPD), a chronic inflammatory disease of the lungs, a new study shows. “Our study reveals elevated expression of [extracellular] CIRP in the lung tissue and [blood] of…
An investigational fixed-dose combination of macitentan and tadalafil in a single tablet (M/T STCT) led to improvements in blood flow and reductions in a biomarker of heart failure for people with pulmonary arterial hypertension (PAH) who were treatment naïve or previously received monotherapies, according to final…
